Galera(GRTX) - 2024 Q2 - Quarterly Results

Exhibit 99.1 Galera Announces Board Approval of Complete Liquidation and Dissolution Company reports second quarter 2024 financial results MALVERN, Pa. – August 14, 2024 – Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company historically focused on developing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced that its Board of Directors has approved a Plan of Liquidation and Dissolution (Plan of Dissoluti ...